Patents by Inventor John Lee Pace
John Lee Pace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951148Abstract: New improved formulations are described, comprising at least one composition, with or without another composition (at least one second composition), in which the at least one composition, a first composition, is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The at least one second composition may be a streptogramin. The first composition, alone or in combination with another, may be used to improve and/or treat a wide variety of bacterial infections, providing, on its own better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other or alternative inhibitors of lipid A deacetylase, as well as no expected cardiotoxicity. When provided to a susceptible microorganism as a combination described herein, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations).Type: GrantFiled: October 11, 2021Date of Patent: April 9, 2024Assignee: FLEURIR ABX, LLCInventor: John Lee Pace
-
Patent number: 11925653Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.Type: GrantFiled: January 25, 2021Date of Patent: March 12, 2024Assignee: FLEURIR ABX, LLCInventors: John Lee Pace, Marc Edwin Wiles, Stacy Michelle Adams, Elizabeth Hussey
-
Publication number: 20230398101Abstract: Co-agent combinations and/or formulations herein unexpectedly display significantly better antimicrobial activity (e.g., more efficacy and/or more potency) against anaerobic pathogens not previously considered targets. With three or more co-agents, selected from a group of a fosfomycin, a diaminopyridine, a sulfonamide, a beta lactam antibacterial, a bacterial beta-lactamase inhibitor, a bacterial fosfomycin-modifying enzyme, and a bacterial peptidoglycan synthesis inhibitor, the therapeutic potential of the three or more co-agents is expanded by targeting a broader spectrum of pathogens. Co-agents, by unexpected synergistic action in an anaerobic environment, are now active and efficacious against difficult to treat pathogenic anaerobes (including anaerobes that cannot utilize oxygen and/or reside in an anaerobic environment, some being inhibited by oxygen), as well as pathogens considered resistant or intolerant to at least one of the co-agents when used singly in an anaerobic environment.Type: ApplicationFiled: June 9, 2022Publication date: December 14, 2023Applicant: Fleurir ABX LLCInventors: John Lee Pace, Theresa Lynn Hartsell
-
Publication number: 20220233557Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.Type: ApplicationFiled: January 25, 2021Publication date: July 28, 2022Applicant: Fleurir ABX LLCInventors: John Lee PACE, Marc Edwin WILES, Stacy Michelle ADAMS, Elizabeth HUSSEY
-
Patent number: 11141453Abstract: New improved formulations are described, comprising at least one composition, with or without another composition, in which the at least one composition is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The another composition is a streptogramin. Said at least one composition, alone or in combination, may be used to improve and/or treat a wide variety of bacterial infections, providing better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other or alternative inhibitors of lipid A deacetylase. When provided to a susceptible microorganism as a combination described herein, of the at least one composition and the another composition, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations).Type: GrantFiled: June 3, 2019Date of Patent: October 12, 2021Assignee: FLEURIR ABX LLCInventor: John Lee Pace
-
Patent number: 10898501Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.Type: GrantFiled: November 18, 2015Date of Patent: January 26, 2021Assignee: FLEURIR ABX, LLCInventors: John Lee Pace, Marc Edwin Wiles, Stacy Michelle Adams, Elizabeth Hussey
-
Patent number: 10307457Abstract: New improved formulations are described, comprising at least a first composition, with or without a second composition, in which the first composition is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to. The second composition is a streptogramin. Said first composition, alone or in combination, may be used to improve and/or treat a wide variety of bacterial infections, providing better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other inhibitors of lipid A deacetylase. When provided to a susceptible microorganism as a combination of the first composition and the second composition, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations).Type: GrantFiled: January 22, 2018Date of Patent: June 4, 2019Assignee: FLEURIR ABX LLCInventor: John Lee Pace
-
Publication number: 20180369259Abstract: Novel antimicrobial compositions comprise at least a form of a fosfomycin (or suitable analogs, or derivatives thereof), and at least one sulfonamide (or suitable analogs, or derivatives thereof), and/or at least one diaminopyridine (or suitable analogs, or derivatives thereof). Said antimicrobial compositions generally include two or more of said components as a novel combination, provided in a single combination or formulation, or provided independently with overlapping exposures of the two or more components. These novel compositions, when provided as the two or more components, are effective against susceptible microorganisms, and are effective against susceptible drug-resistant microorganisms (e.g., bacteria, parasites), including multi-drug resistant bacteria.Type: ApplicationFiled: November 18, 2015Publication date: December 27, 2018Applicant: Fleurir ABX LLCInventors: John Lee PACE, Marc Edwin WILES, Stacy Michelle ADAMS, Elizabeth HUSSEY
-
Patent number: 9872884Abstract: New improved formulations are described, comprising at least a first composition, with or without a second composition, in which the first composition is an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a susceptible microorganism to which it is provided to, and the second composition is a streptogramin. Said first composition, alone or in combination, may be used to improve and/or treat a wide variety of bacterial infections, providing better efficacy, bioavailability, and/or pharmacokinetics, as compared with at least other inhibitors of lipid A deacetylase. When provided to a susceptible microorganism as a combination of the first composition and the second composition, the combination may be provided independently or may be provided together (co-combined in a same formulation, or in different formulations).Type: GrantFiled: January 8, 2017Date of Patent: January 23, 2018Assignee: FLEURIR ABX LLCInventor: John Lee Pace
-
Patent number: 9539305Abstract: New improved formulations comprising a first composition and a second composition, the first composition being a streptogramin, the second composition being an inhibitor of lipid A deacetylase resulting in permeabilization of an outer membrane of a microorganism to which it is provided to. Said composition, alone or in combination may be used to treat bacterial infections, providing better efficacy, bioavailability and or pharmacokinetics as compared with other antimicrobial agents. The combination may be provided independently or together, and via any route(s) and in any formulation or form.Type: GrantFiled: March 16, 2015Date of Patent: January 10, 2017Assignee: FLEURIR ABX LLCInventor: John Lee Pace
-
Publication number: 20100092443Abstract: The invention relates to the combination of nitrogenated heterocyclic antibacterial compounds of formula (I) with other antibacterial compounds and the use of same as drugs. The nitrogenated heterocyclic compounds are of general formula (I) wherein R1 represents a (CH2)n-NH2 or (CH2)n—NHR radical, where R is a (C1-C6) alkyl and n is equal to 1 or 2; R2 represents a hydrogen atom; R3 and R4 together form an aromatic nitrogenated heterocycle with 5 apexes with 1, 2 or 3 nitrogen atoms optionally substituted by one or several R? groups, R? being selected in the group composed of a hydrogen atom and the alkyl radicals with 1 to 6 carbon atoms, in free form, as zwitterions, and in the form of salts of pharmaceutically acceptable inorganic or organic bases and acids.Type: ApplicationFiled: August 5, 2009Publication date: April 15, 2010Applicant: NovexelInventors: Premavathy Levasseur, John Lee Pace, Kenneth Coleman, John Lowther
-
Patent number: 6083683Abstract: This invention relates generally to in vitro methods for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors thereby producing antigenically enhanced enteric bacteria, to methods for using antigenically enhanced enteric bacteria and to vaccines comprising antigenically enhanced enteric bacteria. A Shigella bacterium having enhanced antigenic property is disclosed. A culture medium useful for culturing the Shigella comprises 0.05% to 3% bile or 0.025% to 0.6% of one or more bile acids or salts. In addition a divalent cation chelator can also be included in the culture medium. The bacteria culture is in a growth phase at early log phase and between early log phase and stationary phase. The enhanced antigenic property is a higher level of an immunogenic antigen when compared to the antigenic property of the same bacteria grown on brain heart infusion broth. Also, antibodies to Shigella bacteria or Shigella bacteria in samples are detected by immunoassays.Type: GrantFiled: January 12, 1999Date of Patent: July 4, 2000Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 6077678Abstract: This invention relates generally to in vitro methods for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors thereby producing antigenically enhanced enteric bacteria, to methods for using antigenically enhanced enteric bacteria and to vaccines comprising antigenically enhanced enteric bacteria. A Campylobacter bacterium having enhanced antigenic property is disclosed. A culture medium useful for culturing the Campylobacteria comprises 0.05% to 3% bile or 0.025% to 0.6% of one or more bile acids or salts. In addition a divalent cation chelator can also be included in the culture medium. The bacteria culture is in a growth phase at early log phase and between early log phase and stationary phase. The enhanced antigenic property is a higher level of an immunogenic antigen when compared to the antigenic property of the same bacteria grown on brain heart infusion broth. Also, antibodies to Campylobacter bacteria or Campylobacteria in samples are detected by immunoassays.Type: GrantFiled: January 27, 1999Date of Patent: June 20, 2000Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 6051416Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically a whole enteric bacterium or components thereof are provided by Helicobacter species. Also there are other enteric bacteria which are useful for the disclosed invention; such as Campylobacter jejuni.Type: GrantFiled: May 29, 1997Date of Patent: April 18, 2000Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5976525Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also disclosed are methods for using the antigenically enhanced bacteria, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Campylobacter species. In addition to this species there are other enteric bacteria, such as Yersinia spp., Bacteroides spp., Klebsiella spp., Gastrospirillum spp., Enterobacter spp., Salmonella spp., Aeromonas spp., Vibrio spp., Clostridium spp., Enterococcus spp., and Escherichia coli, which are useful for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors.Type: GrantFiled: April 7, 1997Date of Patent: November 2, 1999Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5897475Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Helicobacter species. Also there are other enteric bacteria which are useful for the disclosed invention; such as Campylobacter jejuni.Type: GrantFiled: October 3, 1995Date of Patent: April 27, 1999Assignee: Antex Biologics, Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5869066Abstract: This invention relates generally to in vitro methods for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors thereby producing antigenically enhanced enteric bacteria, to methods for using antigenically enhanced enteric bacteria and to vaccines comprising antigenically enhanced enteric bacteria. Further, a vaccine comprising a Campylobacter bacterium having en enhanced antigenic property is disclosed. The culture medium conditions comprise 0.05% to 3% bile or 0.025% to 0.6% of one or more bile acids or salts. In addition a divalent cation chelator can also be included in the culture medium. The bacteria culture is in a growth phase at early log phase and between early log phase and stationary phase. The enhanced antigenic property is a higher level of an immunogenic antigen when compared to the antigenic property of the same bacteria grown on brain heart infusion broth.Type: GrantFiled: May 30, 1997Date of Patent: February 9, 1999Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5858352Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced bacteria for use in vaccines. Also disclosed are methods for using the antigenically enhanced bacteria as well as the vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof, are provided by Shigella species. In addition to this microorganism there are other enteric bacteria, such as Campylobacter species and Helicobacter pylori, which are useful for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors.Type: GrantFiled: May 30, 1997Date of Patent: January 12, 1999Assignee: Antex Biologics Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5681736Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also methods for using the antigenically enhanced bacteria are also disclosed, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Shigella species. Also there are other enteric bacteria which are useful for the disclosed invention; such as bacterial species and strains belonging to the genera Helicobacter and Campylobacter.Type: GrantFiled: October 3, 1995Date of Patent: October 28, 1997Assignee: Antex Biologics, Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey
-
Patent number: 5679564Abstract: Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced enteric bacteria. Also disclosed are methods for using the antigenically enhanced bacteria, as well as vaccines containing the enteric bacteria. Specifically, a whole enteric bacteria or components thereof are provided by Campylobacter species. In addition to this species there are other enteric bacteria, such as Helicobacter pylori, which are useful for inducing or enhancing expression of enteric bacterial antigens and/or virulence factors.Type: GrantFiled: October 3, 1995Date of Patent: October 21, 1997Assignee: Antex Biologics, Inc.Inventors: John Lee Pace, Richard Ives Walker, Steven Michael Frey